JCB logo
PeproTech: Your source for Cell Biology Research Reagents
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published online January 22, 2007
doi:10.1083/jcb.200608167
The Journal of Cell Biology, Vol. 176, No. 3, 355-367
The Rockefeller University Press, 0021-9525 $30.00
© 2007 Chaudhry et al.
This Article
Right arrow Full Text
Right arrow PDF (Full Text)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chaudhry, S. S.
Right arrow Articles by Kielty, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chaudhry, S. S.
Right arrow Articles by Kielty, C. M.
Related Collections
Right arrowRelated Article
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Article

 Fibrillin-1 regulates the bioavailability of TGFß1

Shazia S. Chaudhry1,2, Stuart A. Cain1, Amanda Morgan1, Sarah L. Dallas3, C. Adrian Shuttleworth1, and Cay M. Kielty1,2

1 Wellcome Trust Centre for Cell-Matrix Research and 2 UK Centre for Tissue Engineering, Faculty of Life Sciences, University of Manchester, Manchester M13 9PT, England, UK
3 Department of Oral Biology, School of Dentistry, University of Missouri, Kansas City, MO 64108

Correspondence to Cay M. Kielty: cay.kielty{at}manchester.ac.uk

We have discovered that fibrillin-1, which forms extracellular microfibrils, can regulate the bioavailability of transforming growth factor (TGF) ß1, a powerful cytokine that modulates cell survival and phenotype. Altered TGFß signaling is a major contributor to the pathology of Marfan syndrome (MFS) and related diseases. In the presence of cell layer extracellular matrix, a fibrillin-1 sequence encoded by exons 44–49 releases endogenous TGFß1, thereby stimulating TGFß receptor–mediated Smad2 signaling. This altered TGFß1 bioavailability does not require intact cells, proteolysis, or the altered expression of TGFß1 or its receptors. Mass spectrometry revealed that a fibrillin-1 fragment containing the TGFß1-releasing sequence specifically associates with full-length fibrillin-1 in cell layers. Solid-phase and BIAcore binding studies showed that this fragment interacts strongly and specifically with N-terminal fibrillin-1, thereby inhibiting the association of C-terminal latent TGFß-binding protein 1 (a component of the large latent complex [LLC]) with N-terminal fibrillin-1. By releasing LLC from microfibrils, the fibrillin-1 sequence encoded by exons 44–49 can contribute to MFS and related diseases.

Abbreviations used in this paper: ANOVA, analysis of variance; cbEGF, calcium-binding EGF; HDF, human dermal fibroblast; LAP, latency-associated propeptide; LLC, large latent complex; LTBP, latent TGFß-binding protein; MFS, Marfan syndrome; SLC, small latent complex; TGFßR, TGFß receptor; TSP-1, thrombospondin-1.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article

Liberating TGFß
Mitch Leslie
J. Cell Biol. 2007 176: 245. [Full Text] [PDF]



This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents